| Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ... JAMA neurology 79 (3), 228-243, 2022 | 167 | 2022 |
| Time from diagnosis to institutionalization and death in people with dementia KJ Joling, O Janssen, AL Francke, RA Verheij, BI Lissenberg‐Witte, ... Alzheimer's & Dementia 16 (4), 662-671, 2020 | 85 | 2020 |
| What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review C Tochel, M Smith, H Baldwin, A Gustavsson, A Ly, C Bexelius, M Nelson, ... Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11, 231-247, 2019 | 81 | 2019 |
| Characteristics of subjective cognitive decline associated with amyloid positivity O Janssen, WJ Jansen, SJB Vos, M Boada, L Parnetti, T Gabryelewicz, ... Alzheimer's & Dementia 18 (10), 1832-1845, 2022 | 43 | 2022 |
| Real‐world evidence in Alzheimer's disease: the ROADMAP Data Cube O Janssen, SJB Vos, G García‐Negredo, C Tochel, A Gustavsson, ... Alzheimer's & Dementia 16 (3), 461-471, 2020 | 18 | 2020 |
| ROADMAP consortium (2019) What outcomes are important to patients with mild cognitive impairment or Alzheimer’s disease, their caregivers, and health-care professionals? A … C Tochel, M Smith, H Baldwin, A Gustavsson, A Ly, C Bexelius, M Nelson, ... Alzheimers Dement (Amst) 11, 231-247, 0 | 14 | |
| Duration of care trajectories in persons with dementia differs according to demographic and clinical characteristics O Janssen, SJB Vos, R Handels, L Vermunt, R Verheij, FRJ Verhey, ... Journal of the American Medical Directors Association 21 (8), 1102-1107. e6, 2020 | 13 | 2020 |
| Time from diagnosis to institutionalization and death in people with dementia. Alzheimers Dement. 2020; 16 (4): 662–71 KJ Joling, O Janssen, AL Francke, RA Verheij, BI Lissenberg-Witte, ... | 6 | |
| Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimer’s disease dementia: the amyloid biomarker study O Janssen, WJ Jansen, BM Tijms, NN Maserejian, R Ossenkoppele, ... Alzheimer's & Dementia 17, e054889, 2021 | 3 | 2021 |
| Predictors of preclinical Alzheimer’s disease in persons with subjective cognitive decline: Neuropsychiatry and behavioral neurology/presymptomatic disease/prodromal disease … O Janssen, WJ Jansen, SJB Vos, NN Maserejian, R Ossenkoppele, ... Alzheimer's & Dementia 16, e042658, 2020 | 1 | 2020 |
| Smoking behavior, sleep quality, and physical activity level are associated with cerebral amyloid pathology in non‐demented persons: The Amyloid Biomarker Study JE Oomens, WJ Jansen, O Janssen, NN Maserejian, FRJ Verhey, ... Alzheimer's & Dementia 18, e065504, 2022 | | 2022 |
| Amyloid‐ß aggregation, APOE‐e genotype, and the trajectory of cognitive decline in persons without dementia O Janssen, WJ Jansen, JE Oomens, BM Tijms, NN Maserejian, ... Alzheimer's & Dementia 18, e063055, 2022 | | 2022 |
| Associations of AD risk factors with cerebrospinal fluid ATN biomarker profiles in 10,662 persons without dementia from the Amyloid Biomarker Study WJ Jansen, BM Tijms, O Janssen, JE Oomens, SJB Vos, FRJ Verhey, ... Alzheimer's & Dementia 18, e065447, 2022 | | 2022 |
| Erratum: Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ... JAMA neurology 79, 313, 2022 | | 2022 |
| Novel perspectives from existing data on early Alzheimer’s disease pathology and dementia care use O Janssen | | 2022 |
| Associations of lifestyle factors with amyloid positivity in cognitively normal individuals at different levels of genetic risk: The amyloid biomarker study JE Oomens, WJ Jansen, O Janssen, FRJ Verhey, SJB Vos, PJ Visser, ... Alzheimer's & Dementia 17, e054090, 2021 | | 2021 |
| O5‐09‐02: DURATION OF DEMENTIA AND FORMAL CARE USE: EFFECTS OF AGE, GENDER, LIVING SITUATION, DEMENTIA MEDICATION AND ETHNICITY O Janssen, K Joling, SJB Vos, R Handels, L Vermunt, A Francke, ... Alzheimer's & Dementia 15, P1638-P1639, 2019 | | 2019 |
| P4‐219: THE AMYLOID BIOMARKER STUDY: A DATA SHARING INITIATIVE WJ Jansen, O Janssen, R Ossenkoppele, PJ Visser, ... Alzheimer's & Dementia 15, P1360-P1360, 2019 | | 2019 |
| O2‐09‐06: FREQUENCIES OF CEREBROSPINAL FLUID A/T/N BIOMARKER PROFILES AND THEIR ASSOCIATION WITH MEMORY FUNCTION IN PERSONS WITHOUT DEMENTIA WJ Jansen, BM Tijms, R Ossenkoppele, SJB Vos, FRJ Verhey, PJ Visser, ... Alzheimer's & Dementia 14 (7S_Part_11), P643-P644, 2018 | | 2018 |
| P3‐585: COGNITIVE RESERVE MODULATES THE ASSOCIATION OF CEREBRAL AMYLOID PATHOLOGY WITH COGNITIVE PERFORMANCE IN PERSONS WITH ALZHEIMER'S DISEASE DEMENTIA O Janssen, WJ Jansen, R Ossenkoppele, NN Maserejian, FRJ Verhey, ... Alzheimer's & Dementia 14 (7S_Part_25), P1349-P1350, 2018 | | 2018 |
